Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case

Impact · against what's priced in

Tenax Therapeutics faces a significant valuation hit following the Phase III LEVEL trial's failure to meet its primary and key secondary endpoints. While post-hoc subgroup data suggests efficacy in sicker patients, the resulting regulatory uncertainty and need for new or amended trials create a substantial setback for the drug's approval timeline.

TENX−0.70

No priced-in read yet